• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Climb Bio Inc.

    4/25/25 4:02:59 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    DEFA14A 1 d935430ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    CLIMB BIO, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    Climb BioYour vote matters!PROXY TABULATOR P.O. 8016, CARY, NC 27512-9903Climb Bio, Inc.Annual Meeting of StockholdersWednesday, June 4, 2025 9:00 AM, Eastern TimeAnnual Meeting to be held exclusively via the Internet - please visit www.proxydocs.com/CLYM for more details.You must register to attend the meeting online and/or participate at www.proxydocs.com/CLYMFor a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/CLYMTo vote your proxy while visiting this site, you will need the 12 digit control number in the box below.This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet.If you want to receive a paper or email copy of the proxy materials, you must request one on or before May 23, 2025. There is no charge to you for requesting a copy. Unless requested, you will not otherwise receive a paper or email copy.Proxy Materials: Notice of Meeting and Proxy Statement & Annual Report on Form 10-KImportant Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders To Be Held on June 4, 2025 For Stockholders of Record as of April 7, 2025To request paper copies of the proxy materials, use one of the following methods.* If requesting a copy of the proxy materials by email, please send a blank email with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your email requesting a copy of the proxy materials.Your control numberHave the 12 digit control number located in thebox above available when you access thewebsite and follow the instructions.SEE REVERSE FOR FULL AGENDACopyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    Climb Bio, Inc. Annual Meeting of StockholdersFOR EACH OF THE DIRECTOR NOMINEES IN PROPOSAL 1 AND FOR PROPOSAL 2.PROPOSALThe election of two directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified:Judith Dunn, Ph.D.Stephen Thomas, Ph.D.The ratification of the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.Note: The transaction of any other business that may properly come before the 2025 annual meeting of stockholders or any adjournment or postponement thereof.

    Get the next $CLYM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

      SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

      11/14/24 9:29:34 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Williams Douglas E

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      4/1/25 4:23:03 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Drapkin Kimberlee C

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      4/1/25 4:21:03 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cumbo Alexander

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      4/1/25 4:19:03 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Climb Bio Inc.

      10-Q - Climb Bio, Inc. (0001768446) (Filer)

      5/14/25 7:10:23 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Climb Bio, Inc. (0001768446) (Filer)

      5/14/25 7:05:09 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Climb Bio Inc.

      DEFA14A - Climb Bio, Inc. (0001768446) (Filer)

      4/25/25 4:02:59 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarte

      5/14/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB

      PALM BEACH, Fla., May 8, 2025 /PRNewswire/ -- Exec Edge announced the formal launch of Exec Edge Research, a platform that will publish detailed initiation notes along with quarterly updates. Exec Edge Research is a highly specialized platform focused on US and global equities, with an emphasis on fundamental analysis. Our first round of initiation reports includes Fold Holdings, Inc (NASDAQ:FLD), Climb Bio Inc. (NASDAQ:CLYM), Rex American Resources Corp. (NYSE:REX), The ONE Group Hospitality, Inc. (NASDAQ:STKS) and Aurora Cannabis Inc. (NASDAQ:ACB). Our reports dive deep into

      5/8/25 5:40:00 PM ET
      $ACB
      $CLYM
      $FLD
      $REX
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Finance: Consumer Services
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CLYM
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

      WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. "I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team," said Aoife Brennan, President and CEO of Climb Bio. "Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiat

      2/24/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board

      WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® a

      11/11/24 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Climb Bio with a new price target

      Leerink Partners initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

      12/2/24 9:55:08 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care